{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:31:41Z","timestamp":1791117101668,"version":"4.1.0"},"reference-count":32,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,6,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Loss of heterozygosity affecting chromosome 7q is common in acute myeloid leukemia and myelodysplastic syndromes, pointing toward the essential role of this region in disease phenotype and clonal evolution. The higher resolution offered by recently developed genomic platforms may be used to establish more precise clinical correlations and identify specific target genes. We analyzed a series of patients with myeloid disorders using recent genomic technologies (1458 by single-nucleotide polymorphism arrays [SNP-A], 226 by next-generation sequencing, and 183 by expression microarrays). Using SNP-A, we identified chromosome 7q loss of heterozygosity segments in 161 of 1458 patients (11%); 26% of chronic myelomonocytic leukemia patients harbored 7q uniparental disomy, of which 41% had a homozygous EZH2 mutation. In addition, we describe an SNP-A\u2013isolated deletion 7 hypocellular myelodysplastic syndrome subset, with a high rate of progression. Using direct and parallel sequencing, we found no recurrent mutations in typically large deletion 7q and monosomy 7 patients. In contrast, we detected a markedly decreased expression of genes included in our SNP-A defined minimally deleted regions. Although a 2-hit model is present in most patients with 7q uniparental disomy and a myeloproliferative phenotype, haplodeficient expression of defined regions of 7q may underlie pathogenesis in patients with deletions and predominant dysplastic features.<\/jats:p>","DOI":"10.1182\/blood-2011-12-397620","type":"journal-article","created":{"date-parts":[[2012,5,3]],"date-time":"2012-05-03T00:17:57Z","timestamp":1336004277000},"page":"6109-6117","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":109,"title":["Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis"],"prefix":"10.1182","volume":"119","author":[{"given":"Andres","family":"Jerez","sequence":"first","affiliation":[{"name":"Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Makishima","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Verma","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine, Bronx, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Jankowska","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartlomiej","family":"Przychodzen","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Visconte","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon V.","family":"Tiu","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L.","family":"O'Keefe","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azim M.","family":"Mohamedali","sequence":"additional","affiliation":[{"name":"Department of Haematological Medicine, King's College London School of Medicine, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin G.","family":"Kulasekararaj","sequence":"additional","affiliation":[{"name":"Department of Haematological Medicine, King's College London School of Medicine, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pellagatti","sequence":"additional","affiliation":[{"name":"LLR Molecular Haematology Unit, Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"McGraw","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Muramatsu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison R.","family":"Moliterno","sequence":"additional","affiliation":[{"name":"Divisions of Hematology and Hematological Malignancy, Departments of Internal Medicine and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkael A.","family":"Sekeres","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"McDevitt","sequence":"additional","affiliation":[{"name":"Divisions of Hematology and Hematological Malignancy, Departments of Internal Medicine and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Kojima","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"List","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Boultwood","sequence":"additional","affiliation":[{"name":"LLR Molecular Haematology Unit, Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam J.","family":"Mufti","sequence":"additional","affiliation":[{"name":"Department of Haematological Medicine, King's College London School of Medicine, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw P.","family":"Maciejewski","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"13","key":"2019111807533864900_B1","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group Study.","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood"},{"issue":"3","key":"2019111807533864900_B2","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/sj.leu.2401342","article-title":"Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. European Working Group on MDS in Childhood (EWOG-MDS).","volume":"13","author":"Hasle","year":"1999","journal-title":"Leukemia"},{"issue":"6","key":"2019111807533864900_B3","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes.","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"3","key":"2019111807533864900_B4","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111807533864900_B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-4608(94)90174-0","article-title":"Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia.","volume":"73","author":"Swansbury","year":"1994","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"2019111807533864900_B6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cncr.26279","article-title":"Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome.","volume":"118","author":"Cordoba","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"2019111807533864900_B7","first-page":"370","article-title":"Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations.","volume":"9","author":"Lai","year":"1995","journal-title":"Leukemia"},{"issue":"7","key":"2019111807533864900_B8","first-page":"865","article-title":"NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).","volume":"89","author":"Fidler","year":"2004","journal-title":"Haematologica"},{"issue":"24","key":"2019111807533864900_B9","doi-asserted-by":"crossref","first-page":"10349","DOI":"10.1158\/0008-5472.CAN-08-2754","article-title":"250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies.","volume":"68","author":"Dunbar","year":"2008","journal-title":"Cancer Res"},{"issue":"22","key":"2019111807533864900_B10","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers.","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"issue":"6707","key":"2019111807533864900_B11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/24179","article-title":"The murine gene p27Kip1 is haplo-insufficient for tumour suppression.","volume":"396","author":"Fero","year":"1998","journal-title":"Nature"},{"key":"2019111807533864900_B12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/019262301753178555","article-title":"Is p53 haploinsufficient for tumor suppression? Implications for the p53+\/\u2212 mouse model in carcinogenicity testing.","volume":"29","author":"Venkatachalam","year":"2001","journal-title":"Toxicol Pathol"},{"issue":"7176","key":"2019111807533864900_B13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature06494","article-title":"Identification of RPS14 as a 5q- syndrome gene by RNA interference screen.","volume":"451","author":"Ebert","year":"2008","journal-title":"Nature"},{"issue":"10","key":"2019111807533864900_B14","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3324\/haematol.2011.045591","article-title":"Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.","volume":"96","author":"Stein","year":"2011","journal-title":"Haematologica"},{"issue":"2","key":"2019111807533864900_B15","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1365-2141.2011.08672.x","article-title":"Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.","volume":"155","author":"Pellagatti","year":"2011","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111807533864900_B16","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/leu.2010.31","article-title":"Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.","volume":"24","author":"Pellagatti","year":"2010","journal-title":"Leukemia"},{"key":"2019111807533864900_B17","article-title":"International Standing Committee on Human Cytogenetic Nomenclature.","volume-title":"ISCN 2009: An International System for Human Cytogenetic Nomenclature (2009)","author":"International Standing Committee on Human Cytogenetic Nomenclature","year":"2009"},{"issue":"31","key":"2019111807533864900_B18","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1200\/JCO.2009.21.9840","article-title":"New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia.","volume":"27","author":"Tiu","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111807533864900_B19","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"issue":"10","key":"2019111807533864900_B20","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/leu.2010.167","article-title":"Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies.","volume":"24","author":"Makishima","year":"2010","journal-title":"Leukemia"},{"issue":"8","key":"2019111807533864900_B21","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"issue":"1","key":"2019111807533864900_B22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/path.2375","article-title":"High frequency of copy-neutral LOH in MUTYH-associated polyposis carcinomas.","volume":"216","author":"Middeldorp","year":"2008","journal-title":"J Pathol"},{"issue":"3","key":"2019111807533864900_B23","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia.","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"issue":"8","key":"2019111807533864900_B24","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1182\/blood-2006-03-010777","article-title":"Current concepts in the pathophysiology and treatment of aplastic anemia.","volume":"108","author":"Young","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2019111807533864900_B25","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.leukres.2007.08.006","article-title":"Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome.","volume":"32","author":"Yue","year":"2008","journal-title":"Leuk Res"},{"issue":"3","key":"2019111807533864900_B26","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/sj.leu.2405076","article-title":"Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-\/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies.","volume":"22","author":"Huang","year":"2008","journal-title":"Leukemia"},{"issue":"12","key":"2019111807533864900_B27","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2011.36.1824","article-title":"Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited.","volume":"30","author":"Jerez","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111807533864900_B28","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.leukres.2010.03.022","article-title":"Does monosomy 5 really exist in myelodysplastic syndromes and acute myeloid leukemia?","volume":"34","author":"Galv\u00e1n","year":"2010","journal-title":"Leuk Res"},{"issue":"6","key":"2019111807533864900_B29","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/blood.V96.6.2012","article-title":"Isolation and characterization of hematopoietic progenitor\/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level.","volume":"96","author":"Nilsson","year":"2000","journal-title":"Blood"},{"issue":"8","key":"2019111807533864900_B30","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2007-03-079368","article-title":"The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes.","volume":"110","author":"Nilsson","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2019111807533864900_B31","first-page":"1930","article-title":"Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases.","volume":"88","author":"Le Beau","year":"1996","journal-title":"Blood"},{"issue":"11","key":"2019111807533864900_B32","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1182\/blood.V92.11.4031","article-title":"Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders.","volume":"92","author":"D\u00f6hner","year":"1998","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/25\/6109\/1354154\/zh802512006109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/25\/6109\/1354154\/zh802512006109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T08:07:30Z","timestamp":1574064450000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/25\/6109\/30078\/Loss-of-heterozygosity-in-7q-myeloid-disorders"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,21]]},"references-count":32,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2012,6,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-12-397620","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717950039.793455249","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,21]]}}}